Study detail
Recruiting
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Mayo Clinic
Summary
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
Eligibility
- Age range
- Up to 21 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team * Receiving calaspargase as part of treatment for malignancy Exclusion Criteria: * Age \> 21 years * Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm * Pregnancy
Interventions
- OtherNon-Interventional Study
Non-interventional study
Location
- Mayo Clinic in RochesterRochester, Minnesota